Taken together, these results demonstrated that EZH2 inhibitor EPZ‐6438 upregulated KLF14 expression and ameliorated TAA‐induced rat liver fibrosis (Figure 8G). This evidence concerns the gene KLF14 and Hepatic fibrosis.